Category Archives: Market Access

Drug Reimbursement: Make Room at the Table for Patients and Researchers

At last week’s Partnering for Cures conference held in New York City, several expert panels discussed new angles of approaching solutions to disease, encouraging investment and mitigating inefficiencies in the delivery of medicines within the current healthcare system. A highlight was a session on  “Reimbursement: Can Value Drive Innovation?,” which looked at  defining value in […]
Also posted in Events, FDA, healthcare, pricing | Tagged , , , , , , , , , , , , , , , , | Leave a comment

The Vanishing Rx Patient Assistance Programs?

by Tom Norton In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In response to the Clinton’s charges that the industry was “price gouging,” my firm was proposing that we provide free prescription products to any patients who could not […]
Also posted in Corporate Responsibility, Guest Blog, healthcare, Legal, Patient Communication | Tagged , , , , , , , | Leave a comment

Belviq's Battle of the Bulge

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September. Perhaps the most significant development in obesity of late is the recognition by payers – […]
Also posted in Advertising, FDA, Global, healthcare, Marketing, Patient Communication, People, pricing, Regulatory, Safety, Sales, Strategy | Tagged , , , , , , , , , , , , , , | Leave a comment

National Chains Carefully Circle Obamacare

by Tom Norton While US Pharma anxiously watches the initial roll out of Obamacare, there are those entities closely associated with the innovator Rx business that have a very different view on what Obamacare means to their concerns.  These firms are carefully circling the new law, thoughtfully observing its implementation, and, generally, viewing its startup […]
Also posted in Guest Blog, healthcare, leadership, Legal, Regulatory | Tagged , , , , , , , , , , | Leave a comment

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Also posted in Guest Blog, healthcare, Legal, pricing, R&D, Regulatory, Sales, Strategy | Tagged , , , , , , , , | 1 Comment
  • Categories

  • Meta